Genetic Technologies Ltd. ADR (GENE): Price and Financial Metrics
GET POWR RATINGS... FREE!
GENE POWR Grades
- Sentiment is the dimension where GENE ranks best; there it ranks ahead of 65.8% of US stocks.
- GENE's strongest trending metric is Sentiment; it's been moving up over the last 66 days.
- GENE's current lowest rank is in the Quality metric (where it is better than 0.24% of US stocks).
GENE Stock Summary
- GENE has a higher market value than just 6.18% of US stocks; more precisely, its current market capitalization is $33,902,893.
- GENE's price/sales ratio is 385.28; that's higher than the P/S ratio of 98.89% of US stocks.
- Revenue growth over the past 12 months for Genetic Technologies Ltd comes in at 1,122.17%, a number that bests 99.11% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Genetic Technologies Ltd are NEON, HOLI, CAAS, FF, and IQ.
- Visit GENE's SEC page to see the company's official filings. To visit the company's web site, go to www.gtglabs.com.
GENE Stock Price Chart Interactive Chart >
GENE Price/Volume Stats
| Current price | $1.27 | 52-week high | $5.18 |
| Prev. close | $1.26 | 52-week low | $0.95 |
| Day low | $1.24 | Volume | 12,600 |
| Day high | $1.28 | Avg. volume | 70,557 |
| 50-day MA | $1.70 | Dividend yield | N/A |
| 200-day MA | $2.33 | Market Cap | 19.55M |
Genetic Technologies Ltd. ADR (GENE) Company Bio
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. It operates through the USA and Australia geographical segments. The firm's product BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Latest GENE News From Around the Web
Below are the latest news stories about Genetic Technologies Ltd that investors may wish to consider to help them evaluate GENE as an investment opportunity.
US Patent Office Grants Patent for COVID-19 Risk TestMELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection. The granted US patent covers the proprietary technology incorporated into GENE’s geneType COVID-19 Risk Test, which provides a probability |
GeneType Multi-Test Receives Regulatory Approval for Commercial Release in USA and AustraliaMELBOURNE, Australia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that on February 17, 2022 the Company’s laboratory in Fitzroy, Melbourne has received simultaneous NATA accreditation and US Centers for Medicare and Medicaid Services (CMS) CLIA-certification enabling the commercial launch of the GeneType Multi-Test in Australia a |
Genetic Technologies Reports Q2 FY22 Cash Flow ResultsQ2 momentum sets the stage for a strong FY22MELBOURNE, Australia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a diversified Genomics and AI driven preventative health business, provides its results for the quarter ended December 31, 2021. Highlights: Solid cash balance of A$13.5 million and increased customer receipts of A$1.8 million further extending runway for growth‘One company two brands’ approach leverages EasyDNA |
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a global leader in genomics-based tests in health, wellness and serious disease provides the following business update:Cash Receipts (A$'000) Cash Receipts (A$'000) Forecast 2QFY221 cash receipts +112% versus the prior quarter (1QFY22) to A$1.8 million following the completed integration of EasyDNA in the quarterMulti-Test technical validation complete and submitted to NATA2 and CMS3 for final regulatory approval ahead of the commercial releaseUS patent application for novel geneType COVID-19 Risk Test has been accepted and cross validation study completed in independent cohort confirming test performance and ut |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investor! |
GENE Price Returns
| 1-mo | -26.59% |
| 3-mo | -32.45% |
| 6-mo | -47.08% |
| 1-year | -68.41% |
| 3-year | -53.47% |
| 5-year | -70.87% |
| YTD | -32.45% |
| 2021 | -47.78% |
| 2020 | 80.90% |
| 2019 | -9.54% |
| 2018 | -52.59% |
| 2017 | 7.41% |
Continue Researching GENE
Want to see what other sources are saying about Genetic Technologies Ltd's financials and stock price? Try the links below:Genetic Technologies Ltd (GENE) Stock Price | Nasdaq
Genetic Technologies Ltd (GENE) Stock Quote, History and News - Yahoo Finance
Genetic Technologies Ltd (GENE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...